These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32560565)

  • 1. Preclinical Efficacy and Safety of an Anti-Human VEGFA and Anti-Human NRP1 Dual-Targeting Bispecific Antibody (IDB0076).
    Ko JH; Kwon HS; Kim B; Min G; Shin C; Yang SW; Lee SW; Lee Y; Hong D; Kim YS
    Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32560565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis.
    Kim YJ; Bae J; Shin TH; Kang SH; Jeong M; Han Y; Park JH; Kim SK; Kim YS
    J Control Release; 2015 Oct; 216():56-68. PubMed ID: 26260451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model.
    Mueller T; Freystein J; Lucas H; Schmoll HJ
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31394786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
    Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
    MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity.
    Jia H; Cheng L; Tickner M; Bagherzadeh A; Selwood D; Zachary I
    Br J Cancer; 2010 Feb; 102(3):541-52. PubMed ID: 20087344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1/cMet in colon cancer cells.
    Tomida C; Yamagishi N; Nagano H; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
    Int J Oncol; 2018 Apr; 52(4):1350-1362. PubMed ID: 29532881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.
    Kim YJ; Baek DS; Lee S; Park D; Kang HN; Cho BC; Kim YS
    Cancer Lett; 2019 Dec; 466():23-34. PubMed ID: 31521695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and screening of a novel neuropilin-1 targeted penetrating peptide for anti-angiogenic therapy in glioma.
    Zhao L; Chen H; Lu L; Zhao C; Malichewe CV; Wang L; Guo X; Zhang X
    Life Sci; 2021 Apr; 270():119113. PubMed ID: 33508290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical generation of bispecific antibodies.
    Doppalapudi VR; Huang J; Liu D; Jin P; Liu B; Li L; Desharnais J; Hagen C; Levin NJ; Shields MJ; Parish M; Murphy RE; Del Rosario J; Oates BD; Lai JY; Matin MJ; Ainekulu Z; Bhat A; Bradshaw CW; Woodnutt G; Lerner RA; Lappe RW
    Proc Natl Acad Sci U S A; 2010 Dec; 107(52):22611-6. PubMed ID: 21149738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
    Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
    Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.
    Scheuer W; Thomas M; Hanke P; Sam J; Osl F; Weininger D; Baehner M; Seeber S; Kettenberger H; Schanzer J; Brinkmann U; Weidner KM; Regula J; Klein C
    MAbs; 2016; 8(3):562-73. PubMed ID: 26864324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin Fc-Fused Peptide without C-Terminal Arg or Lys Residue Augments Neuropilin-1-Dependent Tumor Vascular Permeability.
    Baek DS; Kim JH; Kim YJ; Kim YS
    Mol Pharm; 2018 Feb; 15(2):394-402. PubMed ID: 29232521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in
    Xiong C; Mao Y; Wu T; Kang N; Zhao M; Di R; Li X; Ji X; Liu Y
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression.
    Geretti E; van Meeteren LA; Shimizu A; Dudley AC; Claesson-Welsh L; Klagsbrun M
    Mol Cancer Res; 2010 Aug; 8(8):1063-73. PubMed ID: 20651020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting.
    Pan Q; Chathery Y; Wu Y; Rathore N; Tong RK; Peale F; Bagri A; Tessier-Lavigne M; Koch AW; Watts RJ
    J Biol Chem; 2007 Aug; 282(33):24049-56. PubMed ID: 17575273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin.
    Kou G; Shi J; Chen L; Zhang D; Hou S; Zhao L; Fang C; Zheng L; Zhang X; Liang P; Zhang X; Li B; Guo Y
    Cancer Lett; 2010 Dec; 299(2):130-6. PubMed ID: 20826049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF (Vascular Endothelial Growth Factor) Induces NRP1 (Neuropilin-1) Cleavage via ADAMs (a Disintegrin and Metalloproteinase) 9 and 10 to Generate Novel Carboxy-Terminal NRP1 Fragments That Regulate Angiogenic Signaling.
    Mehta V; Fields L; Evans IM; Yamaji M; Pellet-Many C; Jones T; Mahmoud M; Zachary I
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1845-1858. PubMed ID: 29880492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
    Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
    J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropilin-1 drives tumor-specific uptake of chlorotoxin.
    McGonigle S; Majumder U; Kolber-Simonds D; Wu J; Hart A; Noland T; TenDyke K; Custar D; Li D; Du H; Postema MHD; Lai WG; Twine NC; Woodall-Jappe M; Nomoto K
    Cell Commun Signal; 2019 Jun; 17(1):67. PubMed ID: 31208428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.